Targeting EZH2 for the treatment of soft tissue sarcomas

Abstract

Soft tissue sarcomas (STS) are a heterogenous group of rare malignancies of mesenchymal origin, affecting both children and adults. The majority of STS have a poor prognosis and advanced stage at the time of diagnosis. Standard treatments for STS largely constitute tumour resection with chemotherapy and/or radiotherapy, and there has been little significant advancement in the application of novel therapies for treatment of these tumours. The current multimodal approach to therapy often leads to long-term side effects, and for some patients, resistance to cytotoxic agents is associated with local recurrence and/or metastasis. There is, therefore, a need for novel therapeutic strategies for the treatment of STS. Recent advances in epigenetics have implicated the histone methyltransferase, EZH2, in the development and progression of diseases such as breast cancer, lymphoma and more recently STS. Here we will review the current literature for EZH2 in STS, including high expression of EZH2 in STS and correlation of this with specific features of malignancy (metastasis, histological grade, and prognosis). The effects of targeting EZH2 using RNA interference and small molecule inhibitors will also be reviewed and the potential for the use of EZH2 inhibition in therapeutic strategies for STS patients will be discussed.

Keywords

EZH2 / epigenetics / therapy

References

[1] Marchesi I,Rizzolio F,Bagella L.The ablation of EZH2 uncovers its crucial role in rhabdomyosarcoma formation.Cell Cycle 2012;11:3828-36 PMCID:PMC3495825

[2] Vella S,Leoncini PP.MicroRNA-101 is repressed by EZH2 and its restoration inhibits tumorigenic features in embryonal rhabdomyosarcoma.Clin Epigenetics 2015;7:82 PMCID:PMC4527101

[3] Shen JK,Gao Y.Targeting EZH2-mediated methylation of H3K27 inhibits proliferation and migration of Synovial Sarcoma in vitro.Sci Rep 2016;6:25239 PMCID:PMC4850444

[4] Kawano S,Tsuda M.Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma.PLoS ONE 2016;11:e0158888 PMCID:PMC4938529

[5] Zhang P,Creighton CJ.EZH2-miR-30d-KPNB1 pathway regulates malignant peripheral nerve sheath tumour cell survival and tumourigenesis.J Pathol 2014;232:308-18 PMCID:PMC4166508

[6] Knutson SK,Wigle TJ.Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2.Proc Natl Acad Sci U S A 2013;110:7922-7. PMCID:PMC3651445

[7] Moreno N.Preclinical evaluation of combined targeted approaches in malignant rhabdoid tumors.Anticancer Res 2016;36:3883-7.

[8] Sun X,Shen JK,Hornicek FJ.Rhabdomyosarcoma: Advances in Molecular and Cellular Biology.Sarcoma 2015;2015:232010 PMCID:PMC4569767

[9] Shi Y,Zhuang YW,Melcher K.Structure of the PRC2 complex and application to drug discovery.Acta Pharmacol Sin 2017;38:963-76 PMCID:PMC5519257

[10] Ciarapica R,Giordano A,Rota R.Enhancer of zeste homolog 2 (EZH2) in pediatric soft tissue sarcomas: first implications.BMC Med 2011;9:63 PMCID:PMC3126730

[11] Ezhkova E,Parker JS.Ezh2 orchestrates gene expression for the stepwise differentiation of tissue-specific stem cells.Cell 2009;136:1122-35 PMCID:PMC2716120

[12] Pereira JD,Smith J,Tarakhovsky A.Ezh2, the histone methyltransferase of PRC2, regulates the balance between self-renewal and differentiation in the cerebral cortex.Proc Natl Acad Sci U S A 2010;107:15957-62 PMCID:PMC2936600

[13] Zhang Q,Zi J.Mutations in EZH2 are associated with poor prognosis for patients with myeloid neoplasms.Genes Dis 2019;6:276-81 PMCID:PMC6997607

[14] Morschhauser F,Chaidos A.Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma.Blood 2019;134:123

[15] Je EM,Yoo NJ.Mutational analysis of PIK3CA, JAK2, BRAF, FOXL2, IDH1, AKT1 and EZH2 oncogenes in sarcomas.APMIS 2012;120:635-9

[16] Deng P,Hong C.Histone methyltransferases and demethylases: regulators in balancing osteogenic and adipogenic differentiation of mesenchymal stem cells.Int J Oral Sci 2015;7:197-204 PMCID:PMC5153596

[17] Dudakovic A,Xu F.Epigenetic Control of Skeletal Development by the Histone Methyltransferase Ezh2.J Biol Chem 2015;290:27604-17 PMCID:PMC4646012

[18] Hemming S,Isenmann S.EZH2 and KDM6A act as an epigenetic switch to regulate mesenchymal stem cell lineage specification.Stem Cells 2014;32:802-15

[19] Yu Y,Yu B.Inhibition of EZH2 Promotes Human Embryonic Stem Cell Differentiation into Mesoderm by Reducing H3K27me3.Stem Cell Reports 2017;9:752-61 PMCID:PMC5599223

[20] Zhang N,Li S,Huang P.High expression of EZH2 as a marker for the differential diagnosis of malignant and benign myogenic tumors.Sci Rep 2018;8:12331 PMCID:PMC6098067

[21] Wilson BG,Shen X.Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation.Cancer Cell 2010;18:316-28 PMCID:PMC2957473

[22] Kadoch C,Keilhack H.PRC2 and SWI/SNF Chromatin Remodeling Complexes in Health and Disease.Biochemistry 2016;55:1600-14

[23] Bracken AP,Verrijzer CP.Dangerous liaisons: interplay between SWI/SNF, NuRD, and Polycomb in chromatin regulation and cancer.Genes Dev 2019;33:936-59 PMCID:PMC6672049

[24] Italiano A.Role of the EZH2 histone methyltransferase as a therapeutic target in cancer.Pharmacol Ther 2016;165:26-31

[25] Yamagishi M.Targeting EZH2 in cancer therapy.Curr Opin Oncol 2017;29:375-81

[26] Walters ZS,Olmos D.JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells.Oncogene 2014;33:1148-57 PMCID:PMC3982124

[27] Ciarapica R,Verginelli F.Deregulated expression of miR-26a and Ezh2 in rhabdomyosarcoma.Cell Cycle 2009;8:172-5

[28] Changchien YC,Papp G.Poorly differentiated synovial sarcoma is associated with high expression of enhancer of zeste homologue 2 (EZH2).J Transl Med 2012;10:216 PMCID:PMC3494513

[29] Yamaga K,Kidani K,Yoshida H.High expression of enhancer of zeste homologue 2 indicates poor prognosis in patients with soft tissue sarcomas.Mol Med Rep 2008;1:633-9

[30] Yalçınkaya U,Özgün G.Enhancer of zeste homologue 2 (EZH2) expression in synovial sarcomas as a promising indicator of prognosis.Bosn J Basic Med Sci 2017;17:302-8 PMCID:PMC5708900

[31] Ramaglia M,Iannotta A.High EZH2 expression is correlated to metastatic disease in pediatric soft tissue sarcomas.Cancer Cell Int 2016;16:59 PMCID:PMC4964052

[32] Cho YJ,Kim EK.Prognostic implications of polycomb proteins ezh2, suz12, and eed1 and histone modification by H3K27me3 in sarcoma.BMC Cancer 2018;18:158 PMCID:PMC5804074

[33] Ciarapica R,Verginelli F.Ezh2 is up-regulated and correlates with Ki67 and CD31 expression in human pediatric rhabdomyosarcoma. Published April 2010.

[34] Wang, Q., Shapiro, K., Lu, Y., Shroyer, K. & Hwang, S. EZH2 expression in rhabdomyosarcoma: A potential biomarker and therapeutic target. Modern Pathology 32 (2019).

[35] Ciarapica R,Adesso L.Pharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMS.BMC Cancer 2014;14:139 PMCID:PMC4016511

[36] Oh TJ,Mohamad T,Davie J.TBX3 represses TBX2 under the control of the PRC2 complex in skeletal muscle and rhabdomyosarcoma.Oncogenesis 2019;8:27 PMCID:PMC6461654

[37] Ciarapica R,Carcarino E.The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx).Oncogene 2014;33:4173-84

[38] Rota R,De Salvo M.453: Enhancer of Zeste Homolog 2 (EZH2) modulation in either embryonal or PAX3-FOXO1 alveolar rhabdomyosarcoma shows different anti-tumoral effects.European Journal of Cancer 2014;50:S109-10

[39] Alimova I,Harris PS.Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells.Neuro Oncol 2013;15:149-60 PMCID:PMC3548579

[40] Popovski D.Targeted catalytic inhibition of EZH2 synergizes with low-dose panobinostat in malignant rhabdoid tumor. Neuro-Oncology 19(2017). Published July 201741.

[41] Constantinidou ., et al. Epigenetic modulation in well differentiated (WD) and dedifferentiated (DD) liposarcoma (LPS): A novel therapeutic approach. Annals of Oncology 27(2016).

[42] Gounder M,Jones RL.Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study.Lancet Oncol 2020;21:1423-32

[43] Italiano A,Toulmonde M.Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.Lancet Oncol 2018;19:649-59

[44] Morschhauser F,Chaidos A.Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.Lancet Oncol 2020;21:1433-42

[45] Yap TA,Giulino-Roth L.Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors.Clin Cancer Res 2019;25:7331-9 PMCID:PMC7377921

[46] Jones BA,Arend RC.Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer.Mol Cancer Ther 2018;17:591-602 PMCID:PMC5939583

[47] Schoffski P,Stacchiotti S.Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with synovial sarcoma (NCT02601950).JCO 2017;35:11057

[48] Marchesi I,Fais M,Giordano A.12-O-tetradecanoylphorbol-13-acetate and EZH2 inhibition: A novel approach for promoting myogenic differentiation in embryonal rhabdomyosarcoma cells.J Cell Physiol 2018;233:2360-5

[49] Wang C.Childhood rhabdomyosarcoma: recent advances and prospective views.J Dent Res 2012;91:341-50 PMCID:PMC3310752

[50] Romanelli A,Fioravanti R.Design of First-in-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity and Biological Evaluation in Cancer Cells.ACS Med Chem Lett 2020;11:977-83 PMCID:PMC7236245

[51] Dawson LE,Hakim AA.Induction of Myogenic Differentiation Improves Chemosensitivity of Chemoresistant Cells in Soft-Tissue Sarcoma Cell Lines.Sarcoma 2020;2020:8647981 PMCID:PMC7136814

[52] Kurmasheva RT,Favours E.Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program.Pediatr Blood Cancer 2017;64:e26218 PMCID:PMC5584632

[53] Unland R,Clemens D,Dirksen U.Analysis of the antiproliferative effects of 3-deazaneoplanocin A in combination with standard anticancer agents in rhabdoid tumor cell lines.Anticancer Drugs 2015;26:301-11

[54] Grinshtein N,Marcellus R.Small molecule epigenetic screen identifies novel EZH2 and HDAC inhibitors that target glioblastoma brain tumor-initiating cells.Oncotarget 2016;7:59360-76 PMCID:PMC5312317

[55] Harding T,Van Ness B.EZH2 inhibitors sensitize myeloma cell lines to panobinostat resulting in unique combinatorial transcriptomic changes.Oncotarget 2018;9:21930-42 PMCID:PMC5955152

[56] Huang JP.EZH2 and histone deacetylase inhibitors induce apoptosis in triple negative breast cancer cells by differentially increasing H3 Lys²⁷ acetylation in the.BIM 14:5735-42 PMCID:PMC5661363

[57] Takashina T,Kikuchi J.Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.Cancer Sci 2016;107:955-62 PMCID:PMC4946723

[58] Lindsay H,Qi L.AT-01 Therapeutic targeting of INI1 deficiency in pediatric atrt: A pre-clinical study utilizing patient derived orthotopic xenograft (PDOX) models.Neuro-Oncology 2015;17:iii1

[59] Zhang A,Ozark P.ATRT-02 Therapeutic targeting of EZH2 and BET BRD4 in AT/RT.Neuro-Oncology2019;21:ii63

[60] Stacchiotti S,Jones R.Safety and efficacy of tazemetostat, a first-in-class EZH2 inhibitor, in patients (pts) with epithelioid sarcoma (ES) (NCT02601950).JCO 2019;37:11003

[61] Stacchiotti S,Tortoreto M.Comparative Assessment of Antitumor Effects and Autophagy Induction as a Resistance Mechanism by Cytotoxics and EZH2 Inhibition in INI1-Negative Epithelioid Sarcoma Patient-Derived Xenograft.Cancers (Basel) 2019;11:1015 PMCID:PMC6678245

[62] Zhang P,Ma X.Antitumor effects of pharmacological EZH2 inhibition on malignant peripheral nerve sheath tumor through the miR-30a and KPNB1 pathway.Mol Cancer 2015;14:55 PMCID:PMC4357176

[63] Fourneaux B,Dadone B.Identifying and targeting cancer stem cells in leiomyosarcoma: prognostic impact and role to overcome secondary resistance to PI3K/mTOR inhibition.J Hematol Oncol 2019;12:11 PMCID:PMC6347793

[64] Velez AM,Singer S.Aberrant expression of epigenetic modifiers in dedifferentiated liposarcoma (DDLS) and the effects of dual inhibition of DNA and histone methylation in DDLS cell lines. Abstract Book: Society of Surgical Oncology 69th Annual Cancer Symposium.Ann Surg Oncol 2016;23,S37-8

[65] Wen Y,Hou Y,Wang Z.Role of EZH2 in cancer stem cells: from biological insight to a therapeutic target.Oncotarget 2017;8:37974-90 PMCID:PMC5514966

[66] Xu K,Groner AC.EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent.Science 2012;338:1465-9 PMCID:PMC3625962

[67] Lee ST,Wu Z.Context-specific regulation of NF-κB target gene expression by EZH2 in breast cancers.Mol Cell 2011;43:798-810

[68] Jung HY,Lee M.PAF and EZH2 induce Wnt/β-catenin signaling hyperactivation.Mol Cell 2013;52:193-205 PMCID:PMC4040269

[69] Shi B,Yang X.Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells.Mol Cell Biol 2007;27:5105-19 PMCID:PMC1951944

[70] Kim E,Woo DH.Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells.Cancer Cell 2013;23:839-52 PMCID:PMC4109796

[71] Wang X,Yu J.Immune modulatory functions of EZH2 in the tumor microenvironment: implications in cancer immunotherapy. Am J Clin Exp Urol 2019;7:85-91. PMCID:PMC6526357

[72] Raj S,Triozzi PL.Addressing the Adult Soft Tissue Sarcoma Microenvironment with Intratumoral Immunotherapy.Sarcoma 2018;2018:9305294 PMCID:PMC6109466

[73] Christofides A,Bardhan K.Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2.Oncotarget 2016;7:85624-40 PMCID:PMC5356764

[74] Carlo V, Mocavini I, Di Croce L. Polycomb complexes in normal and malignant hematopoiesis.J Cell Biol 2019;218:55-69 PMCID:PMC6314559

[75] Karantanos T,Barhdan K,Boussiotis VA.Regulation of T Cell Differentiation and Function by EZH2.Front Immunol 2016;7:172 PMCID:PMC4853381

[76] Stairiker CJ,Salek-Ardakani S.EZH2 as a Regulator of CD8+ T Cell Fate and Function.Front Immunol 2020;11:593203 PMCID:PMC7574680

[77] Herviou L,Cartron G,Moreaux J.EZH2 in normal hematopoiesis and hematological malignancies.Oncotarget 2016;7:2284-96 PMCID:PMC4823035

[78] Li B.EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications.J Hematol Oncol 2019;12:118 PMCID:PMC6868783

[79] Huang S,Zhou J.EZH2 Inhibitor GSK126 Suppresses Antitumor Immunity by Driving Production of Myeloid-Derived Suppressor Cells.Cancer Res 2019;79:2009-20

[80] Goswami S,Zhang J.Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy.J Clin Invest 2018;128:3813-8 PMCID:PMC6118570

[81] Xiao G,Liu CQ.EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma.J Immunother Cancer 2019;7:300 PMCID:PMC6854886

[82] Miranda TB,Yoo CB.DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation.Mol Cancer Ther 2009;8:1579-88 PMCID:PMC3186068